Bibliographies thématiques / Juvenile idiopathic arthritis, adalimumab, immunogenicity

Littérature scientifique sur le sujet « Juvenile idiopathic arthritis, adalimumab, immunogenicity »

Auteur : Grafiati

Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Juvenile idiopathic arthritis, adalimumab, immunogenicity ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

Doeleman, Martijn J. H., Erik M. van Maarseveen et Joost F. Swart. « Immunogenicity of biologic agents in juvenile idiopathic arthritis : a systematic review and meta-analysis ». Rheumatology 58, n^o 10 (26 février 2019) : 1839–49. http://dx.doi.org/10.1093/rheumatology/kez030.

Texte intégral

Résumé :

Abstract Objective The clinical impact of anti-drug antibodies (ADAbs) in paediatric patients with JIA remains unknown. This systematic review and meta-analysis aimed to summarize the prevalence of ADAbs in JIA studies; investigate the effect of ADAbs on treatment efficacy and adverse events; and explore the effect of immunosuppressive therapy on antibody formation. Methods PubMed, Embase and the Cochrane Library were systematically searched to identify relevant clinical trials and observational studies that reported prevalence of ADAbs. Studies were systematically reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses and appropriate proportional and pairwise meta-analyses were performed. Results A total of 5183 references were screened; 28 articles, involving 26 studies and 2354 JIA patients, met eligibility criteria. Prevalence of ADAbs ranged from 0% to 82% across nine biologic agents. Overall pooled prevalence of ADAbs was 16.9% (95% CI, 9.5, 25.9). Qualitative analysis of included studies indicated that antibodies to infliximab, adalimumab, anakinra and tocilizumab were associated with treatment failure and/or hypersensitivity reactions. Concomitant MTX uniformly reduced the risk of antibody formation during adalimumab treatment (risk ratio 0.33; 95% CI 0.21, 0.52). Conclusion The association of ADAbs with treatment failure and hypersensitivity reactions indicates their clinical relevance in paediatric patients with JIA. Based on our findings, we recommend a preliminary course of action regarding immunogenicity of biologic agents in patients with JIA. Further strategies to predict, prevent, detect and manage immunogenicity could optimize treatment outcomes and personalize treatment with biologic therapies.

Styles APA, Harvard, Vancouver, ISO, etc.

Marzan, Katherine Anne B., et Andreas Otto Reiff. « Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis ». Expert Review of Clinical Immunology 4, n^o 5 (septembre 2008) : 549–58. http://dx.doi.org/10.1586/1744666x.4.5.549.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Magli, Adriano, Raimondo Forte, Pasqualina Navarro, Giustina Russo, Francesca Orlando, Loredana Latanza et Maria Alessio. « Adalimumab for juvenile idiopathic arthritis-associated uveitis ». Graefe's Archive for Clinical and Experimental Ophthalmology 251, n^o 6 (1 mars 2013) : 1601–6. http://dx.doi.org/10.1007/s00417-013-2275-x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Denisova, R. V., E. I. Alexeeva, K. B. Isaeva, T. V. Sleptsova, T. M. Bzarova, S. I. Valieva, E. V. Mitenko et al. « ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ». Current pediatrics 12, n^o 6 (7 décembre 2013) : 123. http://dx.doi.org/10.15690/vsp.v12i6.887.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Simpson, K., N. Marlow, J. Shaw et А. V. Rudakova. « PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS ». Pediatric pharmacology 9, n^o 4 (12 août 2012) : 48. http://dx.doi.org/10.15690/pf.v9i4.390.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Ramanan, Athimalaipet V., Andrew D. Dick, Ashley P. Jones, Andrew McKay, Paula R. Williamson, Sandrine Compeyrot-Lacassagne, Ben Hardwick et al. « Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis ». New England Journal of Medicine 376, n^o 17 (27 avril 2017) : 1637–46. http://dx.doi.org/10.1056/nejmoa1614160.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Tynjala, P., K. Kotaniemi, P. Lindahl, K. Latva, K. Aalto, V. Honkanen et P. Lahdenne. « Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis ». Rheumatology 47, n^o 3 (28 novembre 2007) : 339–44. http://dx.doi.org/10.1093/rheumatology/kem356.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Aksenov, A. V., et E. A. Ivanovskaya. « Successful Use of Adalimumab in Children with Uveitis-Associated Juvenile Idiopathic Arthritis ». Doctor.Ru 20, n^o 10 (2021) : 73–75. http://dx.doi.org/10.31550/1727-2378-2021-20-10-73-75.

Texte intégral

Résumé :

Objective of the Paper: To describe clinical cases of successful use of adalimumab in children with uveitis-associated juvenile idiopathic arthritis (JIA). Key Points. One of the extraarticular manifestations of JIA is uveitis, i. e. inflammation of the vascular tract of the eye. JIA-associated uveitis is diagnosed primarily in small girls with oligoarthritis, early seronegative polyarthritis; in patients with arthritis associated with enthesitis and psoriatic arthritis. The article describes clinical cases of the use of adalimumab in JIA and uveitis where the therapy with methotrexate and topical glucocorticosteroids fails. Conclusion. Uveitis-associated JIA is one of the most disabling forms of JIA, since, despite timely and adequate management, very often it results in severe ocular complications: cataract, glaucoma and even blindness. Adalimumab, a human anti-TNFα monoclonal antibody, is available and it helps in achieving uveitis remission where methotrexate and topical glucocorticosteroids fail, as well as in delaying ocular complications. Keywords: juvenile idiopathic arthritis, uveitis, adalimumab, children.

Styles APA, Harvard, Vancouver, ISO, etc.

Chen, Judy L., Parinaz Abiri et Edmund Tsui. « Recent advances in the treatment of juvenile idiopathic arthritis–associated uveitis ». Therapeutic Advances in Ophthalmology 13 (janvier 2021) : 251584142098457. http://dx.doi.org/10.1177/2515841420984572.

Texte intégral

Résumé :

Juvenile idiopathic arthritis–associated uveitis has an estimated prevalence of 10–20% in patients with juvenile idiopathic arthritis, making it the most common cause of chronic anterior uveitis in children. Prompt treatment is important to prevent development of ocular complications and permanent vision loss. In this review, we will discuss the use of immunosuppression in treatment of juvenile idiopathic arthritis–associated uveitis. This will include the use of conventional immunosuppressants, such as methotrexate, biologic anti-tumor necrosis factor agents, such as adalimumab, as well as other anti-tumor necrosis factor agents, including infliximab and golimumab. In addition, we will discuss medications currently in clinical trials or under consideration for juvenile idiopathic arthritis–associated uveitis, including interleukin-6 inhibitors (tocilizumab) and Janus kinase inhibitors (tofacitinib, baricitinib).

Styles APA, Harvard, Vancouver, ISO, etc.

Thorne, Jennifer E. « Adalimumab in the Treatment of Uveitis in Juvenile Idiopathic Arthritis ». New England Journal of Medicine 376, n^o 17 (27 avril 2017) : 1682–83. http://dx.doi.org/10.1056/nejme1701811.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

Marino, Achille. « Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis : incidence and clinical correlations ». Doctoral thesis, 2020. http://hdl.handle.net/2158/1190561.

Texte intégral

Résumé :

it is a prospective observational cohort study recruiting children with juvenile idiopathic arthritis (JIA) on adalimumab. The objective of the study is to assess the presence of anti-adalimumab antibodies and their clinical relevance in a cohort of JIA patients on adalimumab

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

Kashchenko, E., E. Alexeeva, T. Bzarova, S. Valieva, R. Denisova, O. Lomakina, K. Isaeva, M. Soloshenko et A. Karaseva. « AB0951 Factors associated with response to adalimumab treatment in juvenile idiopathic arthritis ». Dans Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.4011.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Caparello, Maria Costanza, Francesca Tirelli, Gabriele Simonini, Rolando Cimaz et Teresa Giani. « AB0948 PARADOXICAL TINEA AMIANTACEA IN A PATIENT WITH JUVENILE IDIOPATHIC ARTHRITIS RECEIVING ADALIMUMAB ». Dans Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4311.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Roshak, K., JM Sopczynski, RM Suehiro et L. Marshall. « THU0519 Etanercept, adalimumab and methotrexate utilization by juvenile idiopathic arthritis patients and the occurrence of uveitis ». Dans Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.1857.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Ruperto, N., H. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic et al. « THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) : strive registry ». Dans Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2010.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Kordić, Nikolina Benco, Ana Kozmar et Alenka Gagro. « 438 Relevance of adalimumab serum concentration and anti-adalimumab antibodies in secondary loss of response in patients with juvenile idiopathic arthritis ». Dans 10th Europaediatrics Congress, Zagreb, Croatia, 7–9 October 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-europaediatrics.438.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Horneff, Gerd, Kisten Minden, Toni Hospach, Ivan Foeldvari, Peter Haas, Angelika Thon, Betina Rogalski et al. « SAT0502 EFFICACY AND SAFETY OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS – 10 YEAR EXPERIENCE USING DATA OF THE BIKER REGISTRY ». Dans Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.1457.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Klein, A., K. Minden, I. Foeldvari, G. Ganser, JP Haas, R. Trauzeddel, A. Hospach, F. Weller-Heinemann et G. Horneff. « THU0507 Long-term experience with adalimumab for the treatment of juvenile idiopathic arthritis. 5- year data from the german biker registry ». Dans Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3457.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Calvo, Inmaculada, Consuelo Modesto, Maria Montoro, Begoña Laiz, Estibaliz Iglesias, Estefanía Quesada-Masachs, B. Lopez-Montesinos et al. « FRI0555 INFLUENCE OF ANTI-TUMORNECROSIS FACTOR (TNF) DRUG IMMUNOGENICITY ON THE TREATMENT EFFECTIVENESS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) USING SERUM CALPROTECTIN AS A DISEASE ACTIVITY MARKER. MULTICENTER STUDY. ITACA STUDY ». Dans Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7963.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Juvenile idiopathic arthritis, adalimumab, immunogenicity"

Li, Biao, Haoran Li, Li Zhang et Yanlin Zheng. Efﬁcacy and safety of adalimumab in the treatment of Juvenile Idiopathic Arthritis-Associated Uveitis : a meta-analysis and systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, novembre 2020. http://dx.doi.org/10.37766/inplasy2020.11.0002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!